West Pharmaceutical Services Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect the eleven nominees listed in the proxy statement as directors, each to serve a one-year term until the 2027 Annual Meeting.

2. 2

   Advisory Vote to Approve Named Executive Officer Compensation

   ManagementBoard: FOR

   Non-binding, advisory vote (Say-on-Pay) to approve the compensation of the Company’s Named Executive Officers as disclosed in the proxy statement.

   More detail

   This non-binding advisory proposal asks shareholders to approve the Company’s Named Executive Officer (NEO) compensation as disclosed in the proxy statement, including the Compensation Discussion and Analysis, tables and narrative. Management seeks this advisory approval to confirm shareholder support for the executive pay program and to inform future compensation decisions; the Compensation Committee uses results to refine pay practices. The CD&A describes a pay-for-performance framework combining base salary, an annual incentive (AIP) tied to consolidated net sales, EPS and operating cash flow, and long-term equity incentives (PSUs, RSUs, options) with multi-year performance metrics such as sales CAGR and ROIC. The Board highlights that prior say-on-pay support was strong (over 94% in 2025) and that the Compensation Committee exercises discretion (e.g., reduced AIP payout for 2025) to align awards with broader shareholder experience. Approving the proposal is not binding, but a FOR vote signals shareholder endorsement of the current design and governance of executive pay; a negative vote would require the Committee to consider adjustments and shareholder feedback. The Board recommends FOR, citing robust governance practices (independent Compensation Committee, independent consultant, clawback policy, share ownership guidelines and anti-hedging policies) and detailed disclosure of pay design, benchmarking and outcomes. Voting FOR supports management’s view that compensation appropriately incentivizes sustainable performance and alignment with shareholder interests, while a vote AGAINST would communicate dissatisfaction and could prompt program changes or increased engagement. Overall, the proposal functions as a governance signal rather than an operational mandate, informing the Committee’s iterative design of compensation to drive long-term value creation.

3. 3

   Ratification of the Appointment of Our Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of PricewaterhouseCoopers LLP as West’s independent registered public accounting firm for 2026.

4. 4

   Shareholder Proposal Regarding an Independent Board Chair Policy

   Shareholder — John Chevedden (beneficial ownerBoard: AGAINST

   A shareholder proposes that the Board adopt a policy (and amend governing documents if necessary) to separate the roles of Chair and CEO and require the Chair to be an independent director.

Upcoming shareholder meetings at West Pharmaceutical Services Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the West Pharmaceutical Services Inc 2026 annual meeting?

West Pharmaceutical Services Inc (WST) holds its 2026 annual shareholder meeting on Monday, May 4, 2026.

What is the record date for the West Pharmaceutical Services Inc 2026 meeting?

The record date for the West Pharmaceutical Services Inc 2026 meeting is Friday, February 27, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for West Pharmaceutical Services Inc's 2026 meeting?

The board is presenting 11 director nominees at the West Pharmaceutical Services Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the West Pharmaceutical Services Inc 2026 meeting?

Shareholders will vote on 4 proposals at the West Pharmaceutical Services Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.